byiShook Opinion
Oct 9, 2024 - 14:30
Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs. The post Travere Therapeutics Hits 15-Month High On A Promising FDA 'Pivot' In Kidney Disease appeared first on Investor's Business Daily.
Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.
The post Travere Therapeutics Hits 15-Month High On A Promising FDA 'Pivot' In Kidney Disease appeared first on Investor's Business Daily.